NCT05917587 Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
| NCT ID | NCT05917587 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Anna Stanhewicz, PhD |
| Condition | Gestational Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-11 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2024-09-11 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.
Eligibility Criteria
Inclusion Criteria: * ≥12 weeks and ≤5 years postpartum * history of GDM or healthy pregnancy Exclusion Criteria: * prediabetes or diabetes (HbA1c ≥5.7%) * current tobacco use * cardiovascular or metabolic disease * cardiovascular or metabolic medication * history of hypertension during pregnancy * current pregnancy
Contact & Investigator
Anna Stanhewicz, PhD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT05917587 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Gestational Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05917587 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05917587 currently recruiting?
Yes, NCT05917587 is actively recruiting participants. Contact the research team at anna-stanhewicz@uiowa.edu for enrollment information.
Where is the NCT05917587 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT05917587 clinical trial?
NCT05917587 is sponsored by Anna Stanhewicz, PhD. The principal investigator is Anna Stanhewicz, PhD at University of Iowa. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.